drug
migalastat hydrochloride
Marketedupdated 6mo agoby $FOLD AMICUS THERAPEUTICS, INC.
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
May 16, 2027
177 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (62)
- Jan 11, 2042method-of-use (U-2371)US 11833164
- Mar 25, 2039method-of-use (U-2371)US 11633388
- Mar 17, 2039compositionUS 11622962
- Feb 20, 2039method-of-use (U-2371)US 11642334
- Feb 16, 2039compositionUS 11826360
- Feb 6, 2039method-of-use (U-2371)US 11357784
- Aug 17, 2038compositionUS 11903938
- May 30, 2038method-of-use (U-2371)US 10251873
- May 30, 2038method-of-use (U-2371)US 10471053
- May 30, 2038method-of-use (U-2371)US 10792278
- May 30, 2038method-of-use (U-2371)US 10792279
- May 30, 2038method-of-use (U-2371)US 10799491
- May 30, 2038method-of-use (U-2371)US 10806727
- May 30, 2038method-of-use (U-2371)US 10849889
- May 30, 2038method-of-use (U-2371)US 10849890
- May 30, 2038method-of-use (U-2371)US 10857141
- May 30, 2038method-of-use (U-2371)US 10857142
- May 30, 2038method-of-use (U-2371)US 10874655
- May 30, 2038method-of-use (U-2371)US 10874656
- May 30, 2038method-of-use (U-2371)US 10874657
- May 30, 2038method-of-use (U-2371)US 11278536
- May 30, 2038method-of-use (U-2371)US 11278537
- May 30, 2038method-of-use (U-2371)US 11278538
- May 30, 2038method-of-use (U-2371)US 11278539
- May 30, 2038method-of-use (U-2371)US 11278540
- May 30, 2038compositionUS 11304940
- May 30, 2038method-of-use (U-2371)US 11357761
- May 30, 2038method-of-use (U-2371)US 11357762
- May 30, 2038method-of-use (U-2371)US 11357763
- May 30, 2038compositionUS 11357764
- May 30, 2038compositionUS 11357765
- May 30, 2038compositionUS 11376244
- May 30, 2038method-of-use (U-2371)US 11389436
- May 30, 2038method-of-use (U-2371)US 11389437
- May 30, 2038compositionUS 11426396
- May 30, 2038method-of-use (U-2371)US 11458128
- May 30, 2038compositionUS 11612593
- May 30, 2038compositionUS 11612594
- May 30, 2038compositionUS 11633387
- May 30, 2038method-of-use (U-2371)US 11666564
- May 30, 2038compositionUS 11786516
- May 30, 2038method-of-use (U-2371)US 11813255
- May 30, 2038compositionUS 12042488
- May 30, 2038compositionUS 12042489
- May 30, 2038method-of-use (U-2371)US 12042490
- May 30, 2038compositionUS 12109205
- May 30, 2038compositionUS 12280042
- Mar 15, 2037method-of-use (U-2371)US 10076514
- Mar 15, 2037method-of-use (U-2371)US 11234972
- Oct 20, 2031method-of-use (U-2371)US RE486084.9y
- Feb 12, 2029method-of-use (U-2371)US 108139212.2y
- Feb 12, 2029method-of-use (U-2371)US 90955842.2y
- Apr 28, 2028method-of-use (U-2371)US 105250451.4y
- Apr 28, 2028method-of-use (U-2371)US 109258661.4y
- Apr 28, 2028method-of-use (U-2371)US 110335381.4y
- Apr 28, 2028method-of-use (U-2372)US 99996181.4y
- May 16, 2027method-of-use (U-2371)US 10383864177d
- May 16, 2027method-of-use (U-2371)US 10406143177d
- May 16, 2027method-of-use (U-2371)US 11241422177d
- May 16, 2027method-of-use (U-2371)US 9000011177d
- May 16, 2027method-of-use (U-2371)US 9480682177d
- May 16, 2027method-of-use (U-2371)US 9987263177d
News(1)
- BioMarin inks up to $475M deal to challenge Fabry ERT incumbentsBioMarin is paying $70 million upfront to license a Fabry disease drug candidate, expanding the franchise it acquired through its $4.8 billion takeover of Amicus Therapeutics.fiercebiotech · 21d ago
Data sources
last refreshed 25m ago
Found something off?
comments(0)
5-min edit window · permanent after that